We also identified the previously reported ESR1-CCDC170 fusion22 in breast cancer (n = 3), associated with CCDC170 elevated expression resulting from recruiting the strong promoter of ESR1 (p = 0.02; Supplementary Fig. S4). Here, CCDC170 is linked to breast carcinoma.